These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 21616520)

  • 1. Clinical efficacy and safety of denosumab in postmenopausal women with low bone mineral density and osteoporosis: a meta-analysis.
    von Keyserlingk C; Hopkins R; Anastasilakis A; Toulis K; Goeree R; Tarride JE; Xie F
    Semin Arthritis Rheum; 2011 Oct; 41(2):178-86. PubMed ID: 21616520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Denosumab update.
    Lewiecki EM
    Curr Opin Rheumatol; 2009 Jul; 21(4):369-73. PubMed ID: 19424068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis.
    Lin T; Wang C; Cai XZ; Zhao X; Shi MM; Ying ZM; Yuan FZ; Guo C; Yan SG
    Int J Clin Pract; 2012 Apr; 66(4):399-408. PubMed ID: 22313934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Wensel TM; Iranikhah MM; Wilborn TW
    Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Denosumab for the reduction of bone loss in postmenopausal osteoporosis: a review.
    Bridgeman MB; Pathak R
    Clin Ther; 2011 Nov; 33(11):1547-59. PubMed ID: 22108301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical use of denosumab for the treatment for postmenopausal osteoporosis.
    Lewiecki EM
    Curr Med Res Opin; 2010 Dec; 26(12):2807-12. PubMed ID: 21050058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
    Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
    Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
    Lewiecki EM; Miller PD; McClung MR; Cohen SB; Bolognese MA; Liu Y; Wang A; Siddhanti S; Fitzpatrick LA;
    J Bone Miner Res; 2007 Dec; 22(12):1832-41. PubMed ID: 17708711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.
    Josse R; Khan A; Ngui D; Shapiro M
    Curr Med Res Opin; 2013 Mar; 29(3):205-16. PubMed ID: 23297819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Denosumab in postmenopausal women with low bone mineral density.
    McClung MR; Lewiecki EM; Cohen SB; Bolognese MA; Woodson GC; Moffett AH; Peacock M; Miller PD; Lederman SN; Chesnut CH; Lain D; Kivitz AJ; Holloway DL; Zhang C; Peterson MC; Bekker PJ;
    N Engl J Med; 2006 Feb; 354(8):821-31. PubMed ID: 16495394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Denosumab, a RANK ligand inhibitor, for postmenopausal women with osteoporosis.
    Sutton EE; Riche DM
    Ann Pharmacother; 2012; 46(7-8):1000-9. PubMed ID: 22837347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Denosumab. The first inhibitor of RANK-ligand for treatment of osteoporosis].
    Bruhn C
    Med Monatsschr Pharm; 2010 Oct; 33(10):370-5. PubMed ID: 21072910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women.
    Hiligsmann M; Reginster JY
    Bone; 2010 Jul; 47(1):34-40. PubMed ID: 20303422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Denosumab in postmenopausal women with low bone mineral density.
    Schwartzman J; Yazici Y
    N Engl J Med; 2006 Jun; 354(22):2390-1; author reply 2390-1. PubMed ID: 16738280
    [No Abstract]   [Full Text] [Related]  

  • 15. Denosumab. Limited efficacy in fracture prevention, too many adverse effects.
    Prescrire Int; 2011 Jun; 20(117):145-8. PubMed ID: 21678700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Denosumab for postmenopausal osteoporosis?
    Drug Ther Bull; 2012 Jan; 50(1):6-8. PubMed ID: 22241889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
    Cummings SR; San Martin J; McClung MR; Siris ES; Eastell R; Reid IR; Delmas P; Zoog HB; Austin M; Wang A; Kutilek S; Adami S; Zanchetta J; Libanati C; Siddhanti S; Christiansen C;
    N Engl J Med; 2009 Aug; 361(8):756-65. PubMed ID: 19671655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture.
    Simon JA; Recknor C; Moffett AH; Adachi JD; Franek E; Lewiecki EM; McClung MR; Mautalen CA; Ragi-Eis S; Nicholson GC; Muschitz C; Nuti R; Törring O; Wang A; Libanati C
    Menopause; 2013 Feb; 20(2):130-7. PubMed ID: 23010883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denosumab in postmenopausal women with low bone mineral density.
    Rifkin WD
    N Engl J Med; 2006 Jun; 354(22):2390-1; author reply 2390-1. PubMed ID: 16742010
    [No Abstract]   [Full Text] [Related]  

  • 20. [The influence and safety of denosumab on bone mineral density of lumbar spine in women with low bone mass: a meta-analysis].
    Zhu X; Chen J
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Jun; 33(6):913-7. PubMed ID: 23803211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.